Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
45 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Innsbruck, Austria
- Research Site
Salzburg, Austria
- Research Site
Vienna, Austria
- Research Site
Vienna, Austria
- Research Site
Edmonton, Alberta, Canada
- Research Site
Brampton, Ontario, Canada
- Research Site
Ottawa, Ontario, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Bordeaux, France
- Research Site
Nantes, France
- Research Site
Paris, France
- Research Site
Villejuif, France
- Research Site
Berlin, Germany
- Research Site
Esslingen a.N., Germany
- Research Site
Großhansdorf, Germany
- Research Site
Heidelberg, Germany
- Research Site
Haifa, Israel
- Research Site
Kfar Saba, Israel
- Research Site
Petah Tikva, Israel
- Research Site
Ramat Gan, Israel
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Seoul, South Korea
- Research Site
Barcelona, Spain
- Research Site
Madrid, Spain
- Research Site
Madrid, Spain
- Research Site
Seville, Spain
- Research Site
Duarte, California, United States
- Research Site
Fullerton, California, United States
- Research Site
La Jolla, California, United States
- Research Site
Los Angeles, California, United States
- Research Site
Washington D.C., District of Columbia, United States
- Research Site
Chicago, Illinois, United States
- Research Site
Baltimore, Maryland, United States
- Research Site
Baltimore, Maryland, United States
- Research Site
Boston, Massachusetts, United States
- Research Site
St Louis, Missouri, United States
- Research Site
New York, New York, United States
- Research Site
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Dec 2017
- Primary completion
- 13 Sept 2024
- Completion
- 11 Sept 2026
- Last update posted
- 27 Oct 2025
- Registered enrollment
- 528
- Registry id
- NCT03334617
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.